Vaughan T J, Osbourn J K, Tempest P R
Cambridge Antibody Technology, Melbourn, Cambridgeshire, UK.
Nat Biotechnol. 1998 Jun;16(6):535-9. doi: 10.1038/nbt0698-535.
Monoclonal antibodies (Mabs) have long been considered a good class of natural drugs, both because they mimic their natural role in the body and because they have no inherent toxicity. Although rodent Mabs are readily generated, their widespread use as therapeutic agents has been hampered because they are recognized as foreign by the patient. Evidently, clinical Mabs should be as human as possible and results with some of the more recently developed chimerized and humanized Mabs are testimony to this. Mabs that are entirely human are now being produced from phage display and transgenic mice. The first fully human Mabs generated by phage display have already entered clinical trials, and together with recent advances in these technologies, may finally realize the full potential of antibodies.
单克隆抗体（Mabs）长期以来一直被认为是一类优良的天然药物，这既是因为它们模拟了其在体内的天然作用，也是因为它们没有内在毒性。尽管鼠源单克隆抗体很容易产生，但它们作为治疗剂的广泛应用受到了阻碍，因为患者会将其识别为外来物质。显然，临床用单克隆抗体应尽可能与人源化，一些最近开发的嵌合和人源化单克隆抗体的结果证明了这一点。完全人源化的单克隆抗体现在正通过噬菌体展示和转基因小鼠来生产。通过噬菌体展示产生的首批完全人源化单克隆抗体已经进入临床试验，并且随着这些技术的最新进展，可能最终实现抗体的全部潜力。
